RS61431B1 - Humanizovana antitela na tau u alchajmerovoj bolesti - Google Patents
Humanizovana antitela na tau u alchajmerovoj bolestiInfo
- Publication number
- RS61431B1 RS61431B1 RS20210132A RSP20210132A RS61431B1 RS 61431 B1 RS61431 B1 RS 61431B1 RS 20210132 A RS20210132 A RS 20210132A RS P20210132 A RSP20210132 A RS P20210132A RS 61431 B1 RS61431 B1 RS 61431B1
- Authority
- RS
- Serbia
- Prior art keywords
- seq
- antibody
- sequence
- variable region
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081809P | 2014-11-19 | 2014-11-19 | |
| PCT/IB2015/002610 WO2016079597A1 (en) | 2014-11-19 | 2015-11-18 | Humanized tau antibodies in alzheimer's disease |
| EP15837211.0A EP3221349B1 (en) | 2014-11-19 | 2015-11-18 | Humanized tau antibodies in alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61431B1 true RS61431B1 (sr) | 2021-03-31 |
Family
ID=55411706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210132A RS61431B1 (sr) | 2014-11-19 | 2015-11-18 | Humanizovana antitela na tau u alchajmerovoj bolesti |
Country Status (24)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN107428820B (zh) * | 2014-11-19 | 2022-03-22 | 阿克松神经系统科学公司 | 在阿尔茨海默氏病中的人源化tau抗体 |
| US10889638B2 (en) * | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| BR112018072394A2 (pt) * | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | anticorpos que reconhecem a tau |
| ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| EP3601335A1 (en) * | 2017-03-28 | 2020-02-05 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| US11958896B2 (en) | 2017-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2019048017A1 (en) * | 2017-09-07 | 2019-03-14 | Danmarks Tekniske Universitet | METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND |
| TWI853617B (zh) | 2017-10-16 | 2024-08-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| MY199514A (en) | 2018-02-01 | 2023-11-02 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
| WO2019161384A1 (en) * | 2018-02-19 | 2019-08-22 | New York University | Tau single domain antibodies |
| MX2020009991A (es) | 2018-03-28 | 2020-10-14 | Axon Neuroscience Se | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. |
| CA3097667A1 (en) * | 2018-05-03 | 2019-11-07 | Washington University | Methods of diagnosing and treating based on site-specific tau phosphorylation |
| US12319929B2 (en) | 2018-05-15 | 2025-06-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| WO2020077380A1 (en) * | 2018-10-17 | 2020-04-23 | The University Of Queensland | Methods and compositions for treating tauopathies |
| CN119409813A (zh) * | 2018-11-08 | 2025-02-11 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| EP4013772A4 (en) * | 2019-08-13 | 2024-06-05 | Washington University | METHODS FOR DETECTING MTBR-TAU ISOFORMS AND THEIR USE |
| WO2021048619A2 (en) | 2019-09-09 | 2021-03-18 | Axon Neuroscience Se | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| AU2020344577A1 (en) | 2019-09-10 | 2022-03-31 | Washington University | Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation |
| US20230035072A1 (en) * | 2019-12-12 | 2023-02-02 | Alector Llc | Methods of use of anti-cd33 antibodies |
| WO2021173962A1 (en) * | 2020-02-28 | 2021-09-02 | Genemo, Inc. | Methods and materials for diagnosis and treatment of neuronal disorder |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| EP4217063A4 (en) * | 2020-09-22 | 2024-10-30 | Kathleen E. Clarence-Smith | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF HUMAN HYPOCHOLINERGIC DISORDERS |
| CN112625129B (zh) * | 2020-11-26 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素23及包含其的试剂盒及其检测方法 |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2024036005A1 (en) * | 2022-08-10 | 2024-02-15 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| CA3237624A1 (en) * | 2023-07-28 | 2025-04-24 | Genentech, Inc. | NEW USES FOR OMALIZUMAB |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| DE69328430T2 (de) | 1992-07-27 | 2001-01-25 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Zielgerichte liposome zur blut-hirne schranke |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CA2142190C (fr) | 1995-02-14 | 1998-01-27 | Marc Lessard | Conduite d'exfiltration d'air use |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| PT2275119E (pt) | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| CA2384006A1 (en) | 1999-09-09 | 2001-03-15 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | A minimal tau peptide for the nucleation of paired helical filaments |
| MXPA02008145A (es) | 2000-02-24 | 2004-04-05 | Univ Washington | Anticuerpos humanizados que secuestran al peptido beta amiloide. |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1554572B1 (en) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1521774B1 (en) | 2002-07-12 | 2008-08-27 | Axon Neuroscience Forschungs- und Entwicklungs Gmbh | Truncated tau proteins |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
| CA2511599A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| KR101438983B1 (ko) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| CN104447992A (zh) | 2004-09-23 | 2015-03-25 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2625198B1 (en) * | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) * | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| AU2012311234B2 (en) | 2011-09-19 | 2017-09-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease |
| WO2013151762A1 (en) * | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
| SG11201504822VA (en) * | 2012-12-21 | 2015-07-30 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
| CN107428820B (zh) * | 2014-11-19 | 2022-03-22 | 阿克松神经系统科学公司 | 在阿尔茨海默氏病中的人源化tau抗体 |
-
2015
- 2015-11-18 CN CN201580072454.2A patent/CN107428820B/zh active Active
- 2015-11-18 AU AU2015348012A patent/AU2015348012B2/en active Active
- 2015-11-18 US US15/528,333 patent/US10160799B2/en active Active
- 2015-11-18 RU RU2017120688A patent/RU2730668C2/ru active
- 2015-11-18 SI SI201531480T patent/SI3221349T1/sl unknown
- 2015-11-18 LT LTEP15837211.0T patent/LT3221349T/lt unknown
- 2015-11-18 BR BR112017010498A patent/BR112017010498A2/pt not_active Application Discontinuation
- 2015-11-18 KR KR1020177016640A patent/KR20170126855A/ko not_active Ceased
- 2015-11-18 ES ES15837211T patent/ES2848376T3/es active Active
- 2015-11-18 HR HRP20210124TT patent/HRP20210124T1/hr unknown
- 2015-11-18 RS RS20210132A patent/RS61431B1/sr unknown
- 2015-11-18 DK DK15837211.0T patent/DK3221349T3/da active
- 2015-11-18 JP JP2017526550A patent/JP6830061B2/ja active Active
- 2015-11-18 SM SM20210055T patent/SMT202100055T1/it unknown
- 2015-11-18 PT PT158372110T patent/PT3221349T/pt unknown
- 2015-11-18 EP EP20198475.4A patent/EP3786182A1/en active Pending
- 2015-11-18 SG SG11201703237VA patent/SG11201703237VA/en unknown
- 2015-11-18 RU RU2020126237A patent/RU2020126237A/ru unknown
- 2015-11-18 WO PCT/IB2015/002610 patent/WO2016079597A1/en not_active Ceased
- 2015-11-18 EP EP15837211.0A patent/EP3221349B1/en active Active
- 2015-11-18 MX MX2017006663A patent/MX388142B/es unknown
- 2015-11-18 CA CA2966964A patent/CA2966964A1/en not_active Abandoned
- 2015-11-18 HU HUE15837211A patent/HUE053239T2/hu unknown
- 2015-11-18 PL PL15837211T patent/PL3221349T3/pl unknown
-
2017
- 2017-04-25 IL IL251921A patent/IL251921B/en unknown
- 2017-05-19 MX MX2021014367A patent/MX2021014367A/es unknown
-
2018
- 2018-11-05 US US16/181,088 patent/US10745469B2/en active Active
-
2020
- 2020-03-18 JP JP2020047903A patent/JP6864763B2/ja active Active
- 2020-07-10 US US16/926,062 patent/US11319363B2/en active Active
- 2020-08-31 AU AU2020227007A patent/AU2020227007B2/en active Active
-
2021
- 2021-01-11 CY CY20211100012T patent/CY1123746T1/el unknown
- 2021-04-02 JP JP2021063583A patent/JP2021119774A/ja active Pending
- 2021-06-21 IL IL284250A patent/IL284250A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11319363B2 (en) | Humanized tau antibodies in Alzheimer's disease | |
| KR102496162B1 (ko) | 트랜스티레틴(ttr) 아밀로이드증의 항체-기반의 치료 및 이를 위한 인간-유래의 항체 | |
| US10336831B2 (en) | Use of anti-endoglin antibodies for treating ocular fibrosis | |
| EP3166688B1 (en) | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy | |
| US20160257755A1 (en) | Anti-endoglin antibodies and uses thereof | |
| CN114008073A (zh) | 抗tdp-43结合分子及其用途 | |
| CN108135986A (zh) | 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 | |
| AU2022390134A1 (en) | Novel molecules for therapy and diagnosis | |
| HK40044666A (en) | Humanized tau antibodies in alzheimer's disease | |
| HK1244495B (en) | Humanized tau antibodies in alzheimer's disease | |
| HK40061324A (en) | Anti-tdp-43 binding molecules and uses thereof | |
| HK40024078A (en) | Human-derived anti-transthyretin antibody, polynucleotide, vector and use thereof | |
| HK1235022A1 (en) | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy | |
| HK1235022B (en) | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |